The open question is whether future argenx trials in other unproven indications will suffer a similar fate, or if this failure is isolated to the unique heterogeneity of Sjögren's.
4. Integration and Execution Risk of M&A
The market cheered the positive Phase 2 celiac data for FB102, which temporarily validated the $2.2 billion Forte acquisition. However, Phase 2 data is historically not a guarantee of Phase 3 success. argenx now bears the burden of integrating a massive new clinical program, funding expensive pivotal Phase 3 trials, and potentially building out an entirely new commercial infrastructure targeting gastrointestinal specialists rather than neurologists. If FB102 stumbles in Phase 3, argenx will be forced to write down a massive multibillion-dollar goodwill impairment, obliterating the narrative of flawless capital allocation.
Near-Term Clinical Catalysts and Remaining Readouts
Despite the Sjögren's setback, argenx has several pivotal readouts that will dictate its near-term commercial viability. An equity analyst must frame the forward-looking risk/reward profile around these impending milestones:
ALKIVIA Trial (Myositis): In August 2026, argenx reported highly positive results for the Phase 3 ALKIVIA trial in autoimmune myositis. Patients treated with VYVGART Hytrulo achieved a statistically significant 15.4-point improvement, marking a massive clinical victory [cite: 23]. ADAPT OCULUS Trial (Ocular MG): Topline Phase 3 results for ocular myasthenia gravis are highly anticipated, as they would allow argenx to capture an even broader segment of the myasthenia gravis market [cite: 1]. Graves' Disease: A registrational study for Graves' disease is scheduled for initiation in late 2026, pushing the FcRn mechanism into a new, highly prevalent endocrine indication [cite: 1]. Thyroid Eye Disease (TED) Caveat: Investors should note that argenx previously attempted to tackle TED with the Phase 3 UplighTED studies, but discontinued the trials in December 2025 due to futility [cite: 24]. This past failure underscores the ongoing clinical execution risk of the "pipeline in a product" strategy.